MARKET

CVM

CVM

CEL-SCI Corp
AMEX
1.910
+0.020
+1.06%
After Hours: 1.830 -0.08 -4.19% 19:55 03/28 EDT
OPEN
1.880
PREV CLOSE
1.890
HIGH
1.910
LOW
1.810
VOLUME
101.90K
TURNOVER
0
52 WEEK HIGH
3.230
52 WEEK LOW
1.040
MARKET CAP
103.10M
P/E (TTM)
-2.7985
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CVM last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at CVM last week (0311-0315)?
Weekly Report · 03/18 11:26
Weekly Report: what happened at CVM last week (0304-0308)?
Weekly Report · 03/11 11:22
CEL-SCI Corporation Issues Letter To Shareholders
CEL-SCI Corporation issues a letter to shareholders. The company says it is moving its cancer drug Multikine forward. The drug is a pre-surgical treatment for head and neck cancer. Company says it has identified the target cancer patient population for the drug.
Benzinga · 03/06 13:47
Weekly Report: what happened at CVM last week (0226-0301)?
Weekly Report · 03/04 11:26
Weekly Report: what happened at CVM last week (0219-0223)?
Weekly Report · 02/26 11:40
Weekly Report: what happened at CVM last week (0212-0216)?
Weekly Report · 02/19 11:43
CEL-SCI Q1 EPS $(0.14) Up From $(0.18) YoY
Benzinga · 02/15 13:12
More
About CVM
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.

Webull offers CEL-SCI Corp stock information, including AMEX: CVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CVM stock methods without spending real money on the virtual paper trading platform.